The immediate termination of the Chief Commercial Officer without a named replacement raises concerns about commercial strategy and pipeline monetization at a sub-$20M market cap biotech. Monitor for a successor appointment and any accompanying 8-K regarding strategic shifts or cost restructuring.
Price Chart
Executive Summary
Celularity Inc. terminated Rick Gonzalez, its Chief Commercial Officer, effective August 5, 2026. No replacement was named, and no reason other than 'terminated' was provided, which is a potentially negative signal for the company's commercial execution at a small-cap biotech with a $20M market cap.
Key Facts
- Rick Gonzalez was terminated as Chief Commercial Officer, effective immediately on August 5, 2026.
- No replacement has been announced.
- The filing uses 'terminated' language, not retirement or resignation.
- No financial figures or severance details were disclosed.
Financial Impact
No dollar figures provided; the departure removes the top commercial officer from a $20M market-cap company with no named successor.
Risk Factors
- Loss of commercial leadership could disrupt revenue-generating activities or partnership negotiations.
- No successor named may indicate difficulty in attracting talent or a broader organizational restructuring.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-036648 |
| Document: 0001493152-26-036648-index-headers.html | 0001493152-26-036648 |
| Document: 0001493152-26-036648-index.html | 0001493152-26-036648 |
| Document: 0001493152-26-036648.txt | 0001493152-26-036648 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 6d ago | 10-K/A | $1.26 | awaiting T+60 | — | $0.7500 (+40.48%) |
Sep 30, 2026 26d ago | Press Release | $1.35 | awaiting T+60 | — | $0.7500 (−44.44%) |
Sep 29, 2026 27d ago | 8-K | $1.35 | awaiting T+60 | — | $0.7500 (−44.44%) |
Sep 28, 2026 28d ago | SC 13D/A | $1.40 | awaiting T+60 | — | $0.7500 (+46.43%) |
Sep 28, 2026 28d ago | 8-K | $1.40 | awaiting T+60 | — | $0.7500 (+46.43%) |
Sep 24, 2026 4w ago | Press Release | $1.32 | awaiting T+60 | — | $0.7500 (−43.18%) |
Sep 14, 2026 6w ago | 8-K | $1.40 | awaiting T+60 | — | $0.7500 (−46.43%) |
Aug 25, 2026 8w ago | Press Release | $0.8804 | awaiting T+60 | — | $0.7500 (+14.81%) |
Aug 7, 2026 11w ago | 8-K | $0.6866 | awaiting T+60 | — | $0.7500 (−9.23%) |
Jun 30, 2026 16w ago | 8-K | $0.5979 $1.15 | ▼ −92.34% | ▼ −88.78% | $0.7500 (−25.44%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers